Glenmark Specialty S.a.

Glenmark Pharmaceuticals S.a.

Glenmark Pharmaceuticals Limited

Sunil Chaudhari

Ulhas R Dhuppad

Suresh Rajurkar

Chandrakant Dhatrak

Franciscus Koppenhagen

Alkesh Kasliwal

Nilesh Jayantilal Jain

Nitin Babulal Bhamre

Girish Ramakrishna Trivedi

Akhilesh Dayanand Sharma

Prashant Dongre

The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.

Tiotropium inhalation solution for nebulization

The present invention relates to a nanoparticulate formulation comprising a transient receptor potential ankyrin-1 receptor ('TRPA1') antagonist. Particularly, the present invention relates to a nanoparticulate formulation comprising a thienopyrimidinedione derivative as a TRPA1 antagonist and a surface stabilizer; a process for preparing such formulation; and its use in treating a respiratory disorder or pain in a subject.

Nanoparticulate formulation comprising a TRPA1 antagonist

The present invention relates to stable fixed dose topical formulations comprising an antiacne agent and an antibiotic, which exhibit storage stability at a temperature of about 40&#xb0; C. and relative humidity of about 75% for a period of at least 3 months. Particularly, the present invention relates to stable fixed dose topical formulations comprising therapeutically effective amounts of (a) adapalene-containing microspheres and (b) clindamycin, a process for their preparation thereof and their use for the treatment of acne.

Stable fixed dose topical formulation

Growing community of inventors

Nashik, India

Sunil Chaudhari